We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Immunity Pharma announced interim results from its Phase 1/2a clinical study with IPL344, an Akt activating disease-modifying drug for the treatment of ALS.